Results 21 to 30 of about 25,107 (224)

TMSOTf assisted synthesis of 2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosylcytosine ([18F]FAC). [PDF]

PLoS ONE, 2018
[18F]FAC (2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosylcytosine, 1) is a versatile probe for imaging deoxycytidine kinase (dCK) expression levels in vivo.
Kishore K Gangangari, John L Humm, Steven M Larson, Naga Vara Kishore Pillarsetty   +3 more
doaj   +1 more source

DCK is an Unfavorable Prognostic Biomarker and Correlated With Immune Infiltrates in Liver Cancer

Technology in Cancer Research & Treatment, 2020
Background: The biological function of deoxycytidine kinase in tumor is not yet clear, and there are a few studies relating to the correlation of deoxycytidine kinase gene with the occurrence and development of liver cancer.
Shu Fang Hu MM, Xia Lin PhD, Lv Ping Xu MBBS, Hong Gang Chen MBBS, Ju Feng Guo MM, Li Jin MM   +5 more
doaj   +1 more source

The Intracellular Localization of Deoxycytidine Kinase [PDF]

Journal of Biological Chemistry, 1998
Deoxycytidine kinase (dCK) catalyzes the rate-limiting step of the deoxynucleoside salvage pathway in mammalian cells and plays a key role in the activation of several pharmacologically important nucleoside analogs. Using a highly specific polyclonal antibody raised against a C-terminal peptide of the human dCK, we analyzed its subcellular localization
P, Hatzis, A S, Al-Madhoon, M, Jüllig, T G, Petrakis, S, Eriksson, I, Talianidis   +5 more
openaire   +2 more sources

Human equilibrative nucleoside transporter 1 (hENT1) and deoxycytidine kinase (DCK) are predictive biomarkers for Gemcitabine-based chemoradiotherapy in resected pancreatic cancer patients: a retrospective cohort study

Al-Azhar Assiut Medical Journal, 2023
Background and Aim Pancreatic cancer is reported to be one of the cancer-related deaths all over the world. Gemcitabine has been identified as one of the important therapies of malignant diseases.
Abdelhalim A Elsherif, Yuzo Kodama, Norimitsu Uza, Mohammed S Hussein, Mostafa Elhawary   +4 more
doaj   +1 more source

ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. [PDF]

, 2017
Leukemia cells rely on two nucleotide biosynthetic pathways, de novo and salvage, to produce dNTPs for DNA replication. Here, using metabolomic, proteomic, and phosphoproteomic approaches, we show that inhibition of the replication stress sensing kinase ...
Abt, Evan R, Braas, Daniel, Capri, Joseph R, Cheng, Chloe M, Czernin, Johannes, Donahue, Timothy R, Faull, Kym F, Herschman, Harvey R, Kim, Woosuk, Kornblum, Harley I, Le, Thuc M, Merkurjev, Daria, Nikanjam, Mina, Poddar, Soumya, Radu, Caius G, Ribas, Antoni, Rix, Peter, Uong, Nhu T, Wei, Liu, Whitelegge, Julian, Zaretsky, Jesse   +20 more
core   +2 more sources

DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma

World Journal of Surgical Oncology, 2020
Background Deoxycytidine kinase (DCK), an enzyme in the nucleoside biosynthetic pathway, can affect the development of immune cells. However, the relationships between the expression of DCK, patient prognosis, and tumor-infiltrating immune cells (TIICs ...
Danjun Song, Yining Wang, Kai Zhu, Lingyu Tian, Qiang Gao, Jian Zhou, Jia Fan, Xiaoying Wang   +7 more
doaj   +1 more source

Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells [PDF]

, 2012
DNA methylation might be the earliest somatic genome changes in prostate cancer that also play an important role in the process of tumor invasion, growth and metastasis.
D'Alessandro, Anna Maria, Di Clemente, Luigi, Di Pasquale, Boris, Dolo, Vincenza, Festuccia, Claudio, Gravina, Giovanni Luca, Mancini, Andrea, Marampon, Francesco, Muzi, Paola, Ranieri, Guido   +9 more
core   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source

Late-onset thymidine kinase 2 deficiency: a review of 18 cases [PDF]

, 2019
BACKGROUND: TK2 gene encodes for mitochondrial thymidine kinase, which phosphorylates the pyrimidine nucleosides thymidine and deoxycytidine. Recessive mutations in the TK2 gene are responsible for the 'myopathic form' of the mitochondrial depletion ...
Caballero Eraso, Candelaria, Domínguez González, Cristina, Fernández Torrón, Roberto, Fuiza Luces, Carmen, García García, Jorge M., Hernández Laín, Aurelio, Hernández Voth, Ana R., Paradas, Carmen, Rivas, Eloy, Sayas Catalán, Javier   +9 more
core   +1 more source

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source